Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Moderate Buy” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $13.00.

FULC has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Fulcrum Therapeutics in a research note on Monday, October 20th. Piper Sandler reissued an “overweight” rating and set a $16.00 price target (up from $12.50) on shares of Fulcrum Therapeutics in a report on Thursday, October 30th. Leerink Partners set a $20.00 price target on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Wall Street Zen downgraded Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Finally, Royal Bank Of Canada raised their price target on Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 30th.

Fulcrum Therapeutics Trading Up 6.3%

Shares of FULC stock opened at $8.15 on Wednesday. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $10.11. The stock has a market cap of $441.08 million, a price-to-earnings ratio of -6.91 and a beta of 3.02. The company’s 50-day moving average price is $8.41 and its 200-day moving average price is $7.30.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, equities research analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several large investors have recently made changes to their positions in the business. Fox Run Management L.L.C. acquired a new stake in Fulcrum Therapeutics during the 3rd quarter valued at $467,000. GSA Capital Partners LLP raised its holdings in shares of Fulcrum Therapeutics by 256.4% during the third quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock worth $1,068,000 after purchasing an additional 83,505 shares during the period. Aberdeen Group plc raised its stake in Fulcrum Therapeutics by 135.0% during the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after acquiring an additional 79,265 shares during the period. Assetmark Inc. bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $88,000. Finally, Principal Financial Group Inc. bought a new stake in Fulcrum Therapeutics in the third quarter valued at $612,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.